Job creations
As the city rapidly develops as a biopharma hub, wet lab space is rapidly dwindling.
Gilead announced its plans to replant some roots back in North Carolina’s Research Triangle. The new site is expected to bring in 275 jobs to the North Hills innovation district.
Centessa Pharmaceuticals and genomics testing firm Sophia Genetics have both announced plans to expand their real estate footprints in Boston.
Philip Dormitzer explained that there are plenty of reasons to be excited about the prophylactic and therapeutic potential of mRNA.
Mammoth will use the funds to build and broaden its stable of next-generation CRISPR products to detect and cure various diseases.
BioLabs is opening its next hub in Dallas in a 37,000-square-foot flexible life science facility. The Biotech+ Hub can accommodate 35 startups, for which it’s now accepting applications.
The 146,000 square foot facility will benefit Umoja Biopharma to eliminate crucial CAR-T production barriers. There’s a lot more going on, know everything here.
Laronde has managed to secure as much as $440 million from a Series B financing round to support as many as 100 Endless RNA (eRNA) products and drug programs over the next decade.
The Bay State biopharma industry continues to boom, even during the height of a global pandemic that has caused an economic downturn in other business sectors.
Rubix Life Sciences has launched a dedicated therapeutics division to focus on infectious and neurodegenerative diseases.
PRESS RELEASES